ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / ZYBT / forecast
OSTX (42) RNXT (31) FBIO (39) MNOV (30) ⌘ Pro Terminal →

Zhengye Biotechnology Holding Limited (Class A) (ZYBT) 12-Month Stock Forecast & Price Target Cone

$1.30 -9.09% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.28

Zhengye Biotechnology Holding Limited (Class A) (ZYBT) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D- • RED ALERT Cap $67.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ZYBT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ZYBT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Zhengye Biotechnology Holding Limited (Class A) (NASDAQ: ZYBT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.30 (-9.09% 1D, market cap $67.8M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ZYBT ranks #531 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ZYBT compare to OSTX and RNXT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZYBT carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 20.5%, and ROIC of -22.3%. By comparison, OSTX (OS Therapies Incorporated) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $67.6M) and RNXT (RenovoRx Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $67.2M). Among the 5-stock peer group, MNOV leads on earnings multiple (5.7x) while ZYBT leads on capital efficiency (-22.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ZYBT?
▼

Per ZYBT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001975641), Zhengye Biotechnology Holding Limited (Class A) generated $16.6M in revenue (-34.8% YoY), -$10.0M in net income, and $1.8M in free cash flow against $62.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.28 (-1.83%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 10.6% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510040
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-
Cash (10)Whales (8)SEC (7)Macro (8)CEO (7)
Each axis scored 0–20
12M PRICE TARGET CONE-8.5% Base Target
$8 Bull$1 Base$1 Bear
📬 FREE ZYBT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZYBT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (40/100 Composite)
🔍 WHY ZYBT SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+10/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 10.6% FCF Margin ($1.8M FCF) & 20.5% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+8/20 pts (20% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution7/20 pts (-13 pt drag)

Disciplined Float (+0.16% YoY Shares) & executive Form 4 sales trim 13 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
48
Grade D$1.73-19.1% Next Q
Q2 (-2Q)
45
Grade D$1.40+7.1% Next Q
Q3 (-1Q)
43
Grade D$1.50-13.3% Next Q
Current
40
Grade D-$1.30-7.4% Hist 90D α
Trajectory: D (48) → D- (40)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ZYBT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ZYBT currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.48) and Max Pain ($1.37) forces dealer call-delta covering toward $8.41.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZYBT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ZYBT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 40%NO 60%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your ZYBT Position Size: $10,000

Shares at $1.30: 7692.3 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $0.93
$7,154
$-2,846 (-28.5%)
12M Consensus BaseTarget $1.19
$9,154
$-846 (-8.5%)
12M Bull Case BreakoutTarget $8.41
$64,692
+$54,692 (+546.9%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$174%A
Goldman SachsSector Coverage LeadUNDERPERFORM$869%B
JP MorganUS Large-Cap ResearchSELL$158%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ZYBT)

  • ✓Walkthrough of ZYBT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ZYBT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +41.30%🛡️ HOLDING TREND SUPPORT
2026-10-30O $1.17H $1.40L $1.17C $1.30VOL 122.9K
RES: $3.19SUP: $1.08SMA50: $1.48SMA200: $1.16
$8.53$6.38$4.24$2.10$-0.05RES $3.19SUP $1.08$1.302026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ZYBT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ZYBT Butterfly Map → + Track ZYBT →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. -34.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ZYBT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ZYBT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ZYBT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZYBT)

Health Care Rank #531 of 1016 ⚔️ OSTX vs ZYBT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ZYBT vs. OSTX, RNXT, FBIO, MNOV)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Zhengye Biotechnology Holding Limited (Class A) (ZYBT) ranks #531 by composite RQD confidence (40/100, grade D-) and #710 by equity capitalization ($67.8M). Within this direct 5-issuer industry benchmark cohort, MNOV leads on earnings valuation at 5.7x trailing P/E, while ZYBT leads on capital efficiency and profitability with -22.3% ROIC and 20.5% gross margin. OSTX currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with ZYBT at 40/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ZYBT ACTIVE
Zhengye Biotechnology Holding Limited (Class A)
D- 40/100 — 20.5% -22.3% -9.09% $67.8M Benchmark Subject
OSTX
OS Therapies Incorporated
D- 42/100 — — -35.0% -4.61% $67.6M /ostx-vs-zybt →
RNXT
RenovoRx Inc.
E 31/100 — 70.9% -35.0% -10.74% $67.2M /rnxt-vs-zybt →
FBIO
Fortress Biotech Inc.
D- 39/100 — 66.9% -35.0% -4.00% $66.7M /fbio-vs-zybt →
MNOV
Medicinova Inc
E 30/100 5.7x — -35.0% 0.00% $68.9M /mnov-vs-zybt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001975641

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Zhengye Biotechnology Holding Limited (Class A) (ZYBT) reported GAAP revenue of $16.6M (-34.8% vs. FY2024 revenue of $25.5M ) , GAAP net income of -$10.0M, operating cash flow of $1.9M, and free cash flow of $1.8M (-53.0% YoY). On the balance sheet, ZYBT closed FY2025 with $62.4M in total assets against $0 in total debt (Altman Z-Score: 1.90, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $16.6M -$10.0M $1.9M $1.8M $62.4M —
FY2024 (FY) 2024-12-31 $25.5M $1.6M $5.6M $3.8M $67.6M $658.0K

3. ZYBT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ZYBT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Zhengye Biotechnology Holding Limited (Class A) (NASDAQ: ZYBT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.30 (-9.09% 1D, market cap $67.8M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ZYBT ranks #531 in composite RQD confidence.

How does ZYBT compare to OSTX and RNXT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZYBT carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 20.5%, and ROIC of -22.3%. By comparison, OSTX (OS Therapies Incorporated) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $67.6M) and RNXT (RenovoRx Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $67.2M). Among the 5-stock peer group, MNOV leads on earnings multiple (5.7x) while ZYBT leads on capital efficiency (-22.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ZYBT?

Per ZYBT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001975641), Zhengye Biotechnology Holding Limited (Class A) generated $16.6M in revenue (-34.8% YoY), -$10.0M in net income, and $1.8M in free cash flow against $62.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ZYBT trading relative to its 50-day, 200-day, and 52-week technical levels?

ZYBT last traded at $1.30 (-9.09% on volume of 122,945 shares), positioning the stock -12.16% below its 50-day simple moving average ($1.48) and +12.07% above its 200-day simple moving average ($1.16). Across its 52-week range of $0.62 to $8.01, ZYBT sits at the 9.2% percentile with a 14-day RSI of 43.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.14 to $1.46).

ZYBT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ZYBT's 12-month stock price target?

Zhengye Biotechnology Holding Limited (Class A) (ZYBT) carries a 12-month consensus base price target of $1.19 (-8.5% from $1.30), with a bull-case target of $8.41 and a bear-case floor of $0.93.

Is ZYBT stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates ZYBT D- (Sell — SELL) with an RQD Confidence score of 40/100.

Direct Sub-Reports: ZYBT RQD Cockpit ZYBT 12M Forecast ZYBT Earnings & Move ZYBT Dividends & DRIP ZYBT Insiders & 13F ZYBT Whale Options ZYBT Profit Sankey ZYBT News & Why
ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ZYBT — Zhengye Biotechnology Holding Limited (Class A): What the Facts Mean to a Prospective Investor

Engine: roarable-bundle-v1
As of: 2026-11-02T15:08:05Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, Zhengye Biotechnology Holding Limited (Class A) (ZYBT) carries a composite score of 40 / 100 (D- — Roarable Sell — Vulnerable Balance Sheet & Flow).\n- Fundamental Cash Engine (10 / 20): Return on invested capital (ROIC) registers at -22.3% with a free cash flow yield of 2.61% and gross margin of 20.5%.\n- Institutional 13F Whale Flow (8 / 20): Tracks institutional accumulation and dark-pool/options positioning relative to the Biotechnology: Pharmaceutical Preparations cohort.\n- Insider & Congressional Conviction (7 / 20): Evaluates open-market Form 4 executive purchases and Congressional PTR disclosures.\n- Macro Regime Fit (8 / 20): Equity beta of 1.00 across the Health Care sector.\n- Forensic Balance-Sheet Shield (7 / 20): Altman Z-Score of 1.90, Piotroski F-Score of 4/9, and Debt-to-Equity of 0.50.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %\n------------------------------\n$1.30$67.8MN/AN/AN/AN/A0.00%1.00$0.62 - $8.01-22.3%

Business & Sector Positioning

Zhengye Biotechnology Holding Limited (Class A) (ZYBT) is a NASDAQ-listed Health Care issuer operating in Biotechnology: Pharmaceutical Preparations with a market capitalization of $0.1B.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Operating within Biotechnology: Pharmaceutical Preparations (Health Care), ZYBT exhibits an operating margin of -60.0% and net margin of -60.0%. Prospective investors should monitor 2nd-order capex cycles, input cost pass-through in gross margin (20.5%), and valuation discipline (current multiple) relative to free cash flow conversion.

Open Questions for Prospective Investors

  • How sustainable is ZYBT's current operating margin (-60.0%) and ROIC (-22.3%) over the next four quarters?\n2. Does the current valuation multiple (current EV/EBITDA) adequately discount macro sensitivity (Beta 1.00) in Biotechnology: Pharmaceutical Preparations?\n3. Will upcoming quarterly cash flow conversion support continued balance-sheet strength (Altman Z 1.90)?

ZYBT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Zhengye Biotechnology Holding Limited (Class A) (ZYBT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ZYBT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ZYBT Bull vs. Bear Conversation Board — What's Your Call at $1.30?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ZYBT 🐻 67% BEARISH CONVICTION
1. Pick Your Side on ZYBT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.14 (-12.3%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ZYBT (D- • RQD 40/100) a Buy at $1.30?

Welcome to the ZYBT (Zhengye Biotechnology Holding Limited (Class A)) Roar Pit. Current RQD Composite is 40/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.09 (-16.2%)
Spot @ $1.30

Pump the brakes on ZYBT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ZYBT, but look at what you are paying: current EV/EBITDA multiples with 20.5% gross margins. Unless Zhengye Biotechnology Holding Limited (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.55 (+19.2%)
Spot @ $1.30

ZYBT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ZYBT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.30 (52-wk range $0.62 - $8.01), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%